Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Not Available
Phase III
Not Available
Not Available
Crispens, Marta
Vanderbilt University


18 Years
Inclusion Criteria:

Female patients ?18 years of age

Histologically confirmed epithelial ovarian cancer and documented disease.

Patients must have platinum-resistant disease

Patients must have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.

ECOG PS 0-1.

Adequate hematological functions:

ANC ? 1000/mm3

PLT ? 100,000/mm3

PT and PTT (seconds)
Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).

Exclusion Criteria:

Non-epithelial tumors (Carcino-sarcomas are excluded)

Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.

History of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.

Previous ovarian cancer treatment with >5 anticancer regimens.

Any prior radiotherapy to the pelvis or whole abdomen.

Inadequate liver function, defined as serum creatinine > ULN, unless calculated creatinine clearance > 50ml/min (by Cockroft & Gault formula):

Serum (total) bilirubin > ULN (Exception: documented Gilbert's disease patients can be enrolled)

Alkaline phosphatase, AST/SGOT or ALT/SGPT ?2.5 x ULN (or ? 5 x ULN in the presence of liver metastases).

Inadequate renal function, defined as:

Serum creatinine > ULN OR

Calculated creatinine clearance
New York Heart Association (NYHA) Grade II or greater congestive heart failure

History of myocardial infarction or unstable angina within 6 months prior to day of randomization.

History of stroke or transient ischemic attack within 6 months prior to day of randomization.

Patient with proliferative and/or vascular retinopathy

Known brain metastases

History of hemoptysis or active GI bleeding within 6 month prior to day of randomization

Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).

History of abdominal fistula or gastrointestinal perforation.

Current signs and symptoms of bowel obstruction

Uncontrolled active infection

Patients who had evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: